NCT06965751View on ClinicalTrials.gov

A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

February 13, 2026

Study Completion Date

May 31, 2026

Conditions
COVID-19 Infection
Interventions
DRUG

PDI204

PDI204 is a fully human, immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein

OTHER

0.9 % saline

0.9% saline used as placebo

Trial Locations (1)

3004

RECRUITING

Nucleus Network, Melbourne

Sponsors

Collaborators (1)

Nucleus Network Ltd
All Listed Sponsors
collaborator

Nucleus Network Ltd

OTHER

collaborator

Syneos Heath

UNKNOWN

lead

University of Melbourne

OTHER

NCT06965751 - A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 | Biotech Hunter | Biotech Hunter